Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Value of In-vitro Testing Anti-cancer Therapy Sensitivity on Tumorspheres From Patients With Metastatic Colorectal Cancer

NCT03251612 is registered in ClinicalTrials.gov with Vejle Hospital as lead sponsor.

NCT NCT03251612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03251612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Value of In-vitro Testing Anti-cancer Therapy Sensitivity on Tumorspheres From Patients With Metastatic Colorectal Cancer
Lead sponsor
Vejle Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 22, 2017
Completion date
March 21, 2022
Enrollment
90 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer metastatic